Taro Terminates Agreement with NovaBiotics
Taro Pharmaceutical Industries Ltd. Ordinary Shares (TARO)
Last taro pharmaceutical industries ltd. ordinary shares earnings: 2/3 05:21 pm
Check Earnings Report
US:NYSE Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=114698&p=irol-irhome
Company Research
Source: Business Wire
License agreement for anti-fungal peptide treatment, Novexatin® HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) announced today that it has terminated the license agreement with NovaBiotics for the onychomycosis drug, Novexatin®. As previously disclosed in May 2018, the Novexatin® clinical study did not meet the main goal of a Phase IIb study under current guidelines of the FDA and did not show superiority over the placebo. Upon further analysis and evaluation, the Company has decided to terminate its agreement with NovaBiotics. About Taro Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro
Show less
Read more
Impact Snapshot
Event Time:
TARO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARO alerts
High impacting Taro Pharmaceutical Industries Ltd. Ordinary Shares news events
Weekly update
A roundup of the hottest topics
TARO
News
- TARO PHARMACEUTICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Taro Pharmaceutical Industries Ltd. - TAROBusiness Wire
- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.MarketBeat
- Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd. [Yahoo! Finance]Yahoo! Finance
- Taro Announces Extraordinary General Meeting and Ordinary Class Meeting of Shareholders for Approval of Merger with Sun Pharmaceutical Industries Ltd.Business Wire
- Taro Pharmaceutical Industries Ltd. (NYSE: TARO) is now covered by analysts at StockNews.com. They set a "strong-buy" rating on the stock.MarketBeat
TARO
Earnings
- 1/25/24 - Beat
TARO
Sec Filings
- 4/15/24 - Form SC
- 3/20/24 - Form SC
- 3/11/24 - Form SC
- TARO's page on the SEC website